NO314616B1 - Anvendelse av ketoconazol og relaterte substanser i medikamenter for behandling av type II diabetes - Google Patents

Anvendelse av ketoconazol og relaterte substanser i medikamenter for behandling av type II diabetes Download PDF

Info

Publication number
NO314616B1
NO314616B1 NO19970567A NO970567A NO314616B1 NO 314616 B1 NO314616 B1 NO 314616B1 NO 19970567 A NO19970567 A NO 19970567A NO 970567 A NO970567 A NO 970567A NO 314616 B1 NO314616 B1 NO 314616B1
Authority
NO
Norway
Prior art keywords
treatment
drug
ketoconazole
preparation
use according
Prior art date
Application number
NO19970567A
Other languages
English (en)
Norwegian (no)
Other versions
NO970567D0 (no
NO970567L (no
Inventor
Per Maarin
Original Assignee
Cortendo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortendo Ab filed Critical Cortendo Ab
Publication of NO970567D0 publication Critical patent/NO970567D0/no
Publication of NO970567L publication Critical patent/NO970567L/no
Publication of NO314616B1 publication Critical patent/NO314616B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B1/00—Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B1/04—Methods of, or means for, filling the material into the containers or receptacles
    • B65B1/08—Methods of, or means for, filling the material into the containers or receptacles by vibratory feeders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mechanical Engineering (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19970567A 1994-08-09 1997-02-07 Anvendelse av ketoconazol og relaterte substanser i medikamenter for behandling av type II diabetes NO314616B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SE1994/000729 WO1996004912A1 (en) 1994-08-09 1994-08-09 Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes

Publications (3)

Publication Number Publication Date
NO970567D0 NO970567D0 (no) 1997-02-07
NO970567L NO970567L (no) 1997-02-07
NO314616B1 true NO314616B1 (no) 2003-04-22

Family

ID=20393155

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19970567A NO314616B1 (no) 1994-08-09 1997-02-07 Anvendelse av ketoconazol og relaterte substanser i medikamenter for behandling av type II diabetes

Country Status (14)

Country Link
US (2) US5849740A (cs)
EP (2) EP0779810B8 (cs)
JP (1) JP3825469B2 (cs)
KR (1) KR100422162B1 (cs)
AT (1) ATE244009T1 (cs)
CA (1) CA2196174C (cs)
CZ (1) CZ285290B6 (cs)
DE (1) DE69432905T2 (cs)
DK (1) DK0779810T3 (cs)
ES (1) ES2202326T3 (cs)
NO (1) NO314616B1 (cs)
PT (1) PT779810E (cs)
SI (1) SI0779810T1 (cs)
WO (1) WO1996004912A1 (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT779810E (pt) * 1994-08-09 2003-11-28 Cortendo Ab Utilizacao de cetoconazole e substancias relacionadas em medicamentos para o tratamento da diabetes tipo ii
US6642236B1 (en) * 1998-12-14 2003-11-04 Cortendo Ab Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
WO2003055975A2 (en) * 2001-08-23 2003-07-10 New England Biolabs, Inc. A method for engineering strand-specific, sequence-specific, dna-nicking enzymes
ES2346961T3 (es) 2001-11-22 2010-10-22 Biovitrum Ab Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
EP2053409A1 (en) 2003-11-20 2009-04-29 F. Hoffmann-La Roche Ag Specific markers for metabolic syndrome
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
KR101387910B1 (ko) 2005-01-10 2014-04-25 콜텐도 인베스트 아베 당뇨병, 대사 증후군 및 다른 질환을 치료하기 위한 방법및 조성물
US20100280046A1 (en) * 2006-01-10 2010-11-04 Diobex, Inc. Methods and Compositions for Treating Prostate Cancer, Benign Prostatic Hypertrophy, Polycystic Ovary Syndrome and Other Conditions
JP2006206605A (ja) * 2006-03-29 2006-08-10 Metabolic Syndrome I Goeteborg Ab 代謝性症候群の治療薬
EP1886695A1 (en) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
NZ576569A (en) * 2006-10-02 2012-05-25 Cortendo Ab Publ Ketoconazole enantiomer in humans
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432176A (en) * 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
US5175144A (en) * 1988-11-29 1992-12-29 The Johns Hopkins University Method of retarding the progression of chronic renal failure
PT779810E (pt) * 1994-08-09 2003-11-28 Cortendo Ab Utilizacao de cetoconazole e substancias relacionadas em medicamentos para o tratamento da diabetes tipo ii
US5591736A (en) * 1995-07-03 1997-01-07 The Johns Hopkins University Method of retarding the progression of chronic renal failure

Also Published As

Publication number Publication date
ATE244009T1 (de) 2003-07-15
CZ36097A3 (en) 1997-06-11
DE69432905T2 (de) 2004-05-27
WO1996004912A1 (en) 1996-02-22
AU7711894A (en) 1996-03-07
PT779810E (pt) 2003-11-28
EP0779810B8 (en) 2003-09-17
ES2202326T3 (es) 2004-04-01
NO970567D0 (no) 1997-02-07
DK0779810T3 (da) 2003-10-20
CZ285290B6 (cs) 1999-06-16
EP0779810B1 (en) 2003-07-02
KR100422162B1 (ko) 2004-07-07
JPH10510241A (ja) 1998-10-06
US5849740A (en) 1998-12-15
KR970704440A (ko) 1997-09-06
JP3825469B2 (ja) 2006-09-27
AU695011B2 (en) 1998-08-06
NO970567L (no) 1997-02-07
CA2196174A1 (en) 1996-02-22
CA2196174C (en) 2005-03-01
EP0779810A1 (en) 1997-06-25
EP1360960A1 (en) 2003-11-12
SI0779810T1 (en) 2003-12-31
US6166017A (en) 2000-12-26
DE69432905D1 (de) 2003-08-07

Similar Documents

Publication Publication Date Title
NO314616B1 (no) Anvendelse av ketoconazol og relaterte substanser i medikamenter for behandling av type II diabetes
RU2198679C2 (ru) Препараты для лечения метаболического синдрома, содержащие гормон роста человека в комбинации с ингибитором синтеза кортизола
RU2012117563A (ru) Режим дозирования модулятора рецептора s1p
AU2002315814B2 (en) Medicinal composition for treatment of interstitial cystitis
US20020032177A1 (en) Use of D-chiro-inositol in the treatment of conditions associated with hypothalamic gene expression
US7872008B2 (en) Method for treating insulin resistance, abdominal obesity, hypertension, hyperinsulinemia, and elevated blood lipids with a cortisol inhibitor
US4906649A (en) Use of a compound for the treatment of sleep disorders and depression
CN104736151A (zh) 纤维化的柚皮素和积雪草酸组合治疗
WO2021208280A1 (zh) 五谷虫在制备预防和治疗乳腺增生药物中的应用
GB2306321A (en) The use of (+)-catechin in the treatment or prophylaxis of connective tissue disorders
KR20100015923A (ko) 수면관련 호흡 장애를 치료하는 방법들 및 수면관련 호흡 장애 치료용 조성물들
WO2004017973A1 (ja) 統合失調症治療剤
RU2153873C2 (ru) Применение кетоконазола и родственных веществ в лекарствах, предназначенных для лечения диабета типа ii
KR100894385B1 (ko) 녹내장을 치료하기 위한 망막보호제로서의 비여성화에스트로겐의 용도
CN112641765B (zh) 丙泊酚的抗疲劳制药用途
RU2664693C1 (ru) Способ предоперационной подготовки пациентов к офтальмологическим операциям
CN106619586B (zh) L6h3制备帕金森病药物等的应用
KR20030097598A (ko) 코르티솔 길항제를 포함하는 당뇨병 타입 ⅱ의 치료용약제
CN112138013A (zh) I化合物在制备治疗糖尿病及相关病症的药中的用途
CN115025103A (zh) 丹参酮iia磺酸钠在制备药物中的应用
Shakirah STH–Secreting Pituitary Adenoma. Acromegaly Case without Successful Result
EP1990053A1 (en) Pharmaceutical composition for enhancing adiponectin production
CN1665516A (zh) 使用依西美坦治疗不孕症
JP2006206605A (ja) 代謝性症候群の治療薬
HK1077736A (en) Infertility treatment with exemestane

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees